Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 3/20 | 0.48 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | GLS | O94925 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31509580 | 0.89 | ADAMTS4 (0.57) | CYP17A1PPARGPPARAHDAC8MEN1 | |
| SCHEMBL132701 | 0.88 | CYP17A1 (0.76) | CYP17A1DRD2PTGDR2MAPK14NAMPT | |
| SCHEMBL13055402 | 0.87 | CYP17A1 (0.59) | CYP17A1DRD2PTGDR2MAPK14NAMPT | |
| SCHEMBL2244813 | 0.87 | CYP17A1 (0.58) | CYP17A1DRD2PTGDR2MAPK14NAMPT | |
| SCHEMBL10361607 | 0.86 | CYP17A1 (0.61) | CYP17A1DRD2PTGDR2MAPK14NAMPT | |
| SCHEMBL6195004 | 0.86 | CYP17A1 (0.61) | CYP17A1DRD2PTGDR2MAPK14NAMPT | |
| SCHEMBL14870979 | 0.85 | CYP17A1 (0.59) | CYP17A1DRD2PTGDR2MAPK14NAMPT | |
| SCHEMBL243856 | 0.85 | CYP17A1 (0.59) | CYP17A1DRD2PTGDR2MAPK14NAMPT | |
| SCHEMBL13160502 | 0.85 | CYP17A1 (0.59) | CYP17A1DRD2PTGDR2MAPK14NAMPT | |
| SCHEMBL408439 | 0.85 | CYP17A1 (0.59) | CYP17A1DRD2PTGDR2MAPK14NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116102775-B | Porous polyimide film for lithium ion battery and preparation method thereof | 富优特(山东)新材料科技有限公司 | 2023-10-17 | — | — | CN | claimed |
| CN-116102775-A | Porous polyimide film for lithium ion battery and preparation method thereof | 富优特(山东)新材料科技有限公司 | 2023-05-12 | — | — | CN | claimed |
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4593824-A2 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250170252-A1 | QUINONE PROTECTED FORMS AND CONJUGATES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2025-05-29 | — | — | US | disclosed |
| EP-4540245-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LigaChem Biosciences Inc. (KR) | 2025-04-23 | — | — | EP | disclosed |
| EP-4532480-A1 | QUINONE PROTECTED FORMS AND CONJUGATES | Cambridge Enterprise Limited (GB) | 2025-04-09 | — | — | EP | disclosed |
| WO-2024156288-A1 | DNMT1 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | SHANGHAI KYGENT PHARMACEUTICAL CO., LTD (CN) | 2024-08-02 | — | — | WO | disclosed |
| US-20240228447-A1 | SUBSTITUTED NAPHTHYL P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS | GEN1E LIFESCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-11976049-B2 | Substituted naphthyl p38alpha mitogen-activated protein kinase inhibitors | GEN1E LIFESCIENCES INC. (US) | 2024-05-07 | — | — | US | disclosed |
| WO-2023242631-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LEGOCHEM BIOSCIENCES, INC. (KR) | 2023-12-21 | — | — | WO | disclosed |
| EP-1317451-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-20030028022-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2003-02-06 | — | — | US | disclosed |
| WO-2002034745-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-05-02 | — | — | WO | disclosed |
| CN-1075808-C | Aniline derivatives having nitric oxide synthase inhibitory activity | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2001-12-05 | — | — | CN | disclosed |
| WO-2001072751-A1 | PYRROLOPYRIMIDINES AS TYROSINE KINASE INHIBITORS | KNOLL GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2001-10-04 | — | — | WO | disclosed |
| CN-1310169-A | Anils with nitric oxide synzyme inhibiting function | SHUGAI SEIYAKU K K (JP) | 2001-08-29 | — | — | CN | disclosed |
| EP-1114053-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000017203-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
| CN-1172473-A | Aniline derivatives having nitric oxide synthase inhibitory activity | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1998-02-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976049-B2 | Substituted naphthyl p38alpha mitogen-activated protein kinase inhibitors | MAPK1, MAPK8, MAPKAPK2 | CYP17A1 953/4885DRD2 4848/4885PTGDR2 1467/4885 |
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR5A2, NR3C1 | CYP17A1 61/4885DRD2 3973/4885PTGDR2 2563/4885 |
| US-20240228447-A1 | SUBSTITUTED NAPHTHYL P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPKAPK2 | CYP17A1 953/4885DRD2 4848/4885PTGDR2 1467/4885 |
| US-20030028022-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR3, CCR2 | CYP17A1 2492/4885DRD2 1154/4885PTGDR2 122/4885 |
| US-20250170252-A1 | QUINONE PROTECTED FORMS AND CONJUGATES | NQO1, SQOR, GSTP1 | CYP17A1 261/4885DRD2 359/4885PTGDR2 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.